Translational considerations for cancer nanomedicine
- 1 September 2010
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 146 (2) , 164-174
- https://doi.org/10.1016/j.jconrel.2010.04.008
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapyActa Biomaterialia, 2010
- Fluorescent Nanoprobes as a Biomarker for Increased Vascular Permeability: Implications in Diagnosis and Treatment of Cancer and InflammationBioconjugate Chemistry, 2009
- Pharmacokinetic Allometric Scaling of Antibodies: Application to the First-In-Human Dose EstimationJournal of Pharmaceutical Sciences, 2009
- The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing miceJournal of Controlled Release, 2009
- Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to HumansJournal of Pharmaceutical Sciences, 2004
- Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in HumansJournal of Pharmaceutical Sciences, 2003
- Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activityBiochimica et Biophysica Acta (BBA) - Biomembranes, 2002
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsBritish Journal of Cancer, 2001
- Interspecies Scaling of Maximum Tolerated Dose of Anticancer Drugs: Relevance to Starting Dose for Phase I Clinical TrialsClinical Journal of Sport Medicine, 2001
- A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotidesPublished by Elsevier ,1999